NATURECELL CO.,LTD.
Manufactures food, beverages, and cosmetics; researches stem cell therapies.
007390 | KO
Overview
Corporate Details
- ISIN(s):
- KR7007390008
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 영등포구 국회대로76길 10 5층, 서울특별시
- Website:
- http://en.naturecell.co.kr/
- Sector:
- Manufacturing
- Industry:
- Manufacture of other food products
Description
NATURECELL CO.,LTD. is a diversified company operating across the food, beverage, cosmetics, and biotechnology sectors. The company manufactures and sells a range of products including canned goods, health functional foods, and fruit juices. In addition to its consumer goods, NATURECELL has a significant focus on its high-tech biotechnology division, which is dedicated to stem cell research and development. This division conducts clinical trials for potential therapeutic applications, with a noted emphasis on treatments for degenerative diseases such as Alzheimer's.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-09-28 00:00 |
전환가액의조정(제3회차)
|
Korean | 11.6 KB | ||
| 2020-08-26 00:00 |
증권발행결과(자율공시)(제3회차 CB)
|
Korean | 5.9 KB | ||
| 2020-08-24 00:00 |
주요사항보고서(전환사채권발행결정)
|
Korean | 36.5 KB | ||
| 2020-08-14 00:00 |
반기보고서 (2020.06)
|
Korean | 1.2 MB | ||
| 2020-08-13 00:00 |
투자판단관련주요경영사항(코로나-19(COVID-19)감염으로 인한 폐렴 환자 대상 동종 지방유래 중간엽 줄기세포치료제 아스트로스템-V 미국 1…
|
Korean | 9.6 KB | ||
| 2020-07-20 00:00 |
[기재정정]투자판단관련주요경영사항(알츠하이머병 환자에게서 자가 지방유래 중간엽 줄기세포'아스트로스템'의 유효성 및 안전성을 평가하기 위한 무작…
|
Korean | 18.9 KB | ||
| 2020-06-17 00:00 |
[기재정정]투자판단관련주요경영사항(알츠하이머병 환자에게서 자가 지방유래 중간엽 줄기세포'아스트로스템'의 유효성 및 안전성을 평가하기 위한 무작…
|
Korean | 18.6 KB | ||
| 2020-05-21 00:00 |
투자판단관련주요경영사항(알츠하이머병 환자에게서 자가 지방유래 중간엽 줄기세포'아스트로스템'의 유효성 및 안전성을 평가하기 위한 무작위배정, 이…
|
Korean | 10.3 KB | ||
| 2020-05-18 00:00 |
투자판단관련주요경영사항(코로나-19감염으로 인한 폐렴환자대상 아스트로스템-V 미국 1/2a상 임상시험계획 심사보류(clinical Hold))
|
Korean | 8.6 KB | ||
| 2020-05-15 00:00 |
분기보고서 (2020.03)
|
Korean | 1.1 MB | ||
| 2020-04-20 00:00 |
투자판단관련주요경영사항(중증퇴행성관절염 줄기세포치료제 조인트스템 미국 FDA 제2b/3a상 임상시험계획 승인)
|
Korean | 10.9 KB | ||
| 2020-04-17 00:00 |
투자판단관련주요경영사항(코로나-19 감염으로 인한 폐렴환자 대상 아스트로스템-V 미국 1/2a상 임상시험계획 신청)
|
Korean | 8.7 KB | ||
| 2020-04-08 00:00 |
기업설명회(IR)개최
|
Korean | 7.7 KB | ||
| 2020-03-30 00:00 |
사업보고서 (2019.12)
|
Korean | 479.0 KB | ||
| 2020-03-26 00:00 |
정기주주총회결과
|
Korean | 23.1 KB |
Automate Your Workflow. Get a real-time feed of all NATURECELL CO.,LTD. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for NATURECELL CO.,LTD.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for NATURECELL CO.,LTD. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
